Cargando…

1783. Acute Kidney Injury Associations with Antibiotics: A Pharmacovigilance Study of the US FDA Adverse Event Reporting System

BACKGROUND: Antibiotic-associated acute kidney injury is found to be associated with many antibiotics like vancomycin, fluoroquinolones, penicillin combinations, and trimethoprim–sulfamethoxazole. Other antibiotics may also lead to acute kidney injury. Still, no study has systemically compared the c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kochuparambil, Jose J, Raju, Jomel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679197/ http://dx.doi.org/10.1093/ofid/ofad500.1612

Ejemplares similares

1846. Quality of Life Impairment and Difficulty to Work Associated with Post-COVID Syndrome: A Cross-Sectional Study
por: Kochuparambil, Jose J, et al.
Publicado: (2023)

1977. Comparing Acute Kidney Injury Risk among Antibiotic Classes: A Study of the FDA Adverse Event Reporting System (FAERS)
por: Patek, Taylor M, et al.
Publicado: (2019)

Rhabdomyolysis Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS)
por: Teng, Chengwen, et al.
Publicado: (2019)

Delirium Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS)
por: Teng, Chengwen, et al.
Publicado: (2021)

OpenVigil FDA – Inspection of U.S. American Adverse Drug Events Pharmacovigilance Data and Novel Clinical Applications
por: Böhm, Ruwen, et al.
Publicado: (2016)

Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system
por: Shu, Yamin, et al.
Publicado: (2023)

Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system
por: Shu, Yamin, et al.
Publicado: (2022)

Torsades de pointes and QT prolongation Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System
por: Teng, Chengwen, et al.
Publicado: (2019)

Pharmacovigilance Study of Infigratinib: A Safety Analysis of the FDA Adverse Event Reporting System
por: Zhao, Dehua, et al.
Publicado: (2023)

A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib
por: Yin, Yanchao, et al.
Publicado: (2022)

A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for venetoclax
por: Yang, Yang, et al.
Publicado: (2022)

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib
por: Guo, Menglin, et al.
Publicado: (2022)

2296. Hypoglycemia Risk with Antibiotics: An Epidemiologic Surveillance Study of the FDA Adverse Event Reporting System (FAERS)
por: Kennedy, Kaitlin E, et al.
Publicado: (2019)

Pharmacovigilance of triazole antifungal agents: Analysis of the FDA adverse event reporting system (FAERS) database
por: Zhou, Jianxing, et al.
Publicado: (2022)

A real-world pharmacovigilance analysis of FDA adverse event reporting system database for upadacitinib
por: Wu, Yan, et al.
Publicado: (2023)

Ocular adverse events associated with anti-VEGF therapy: A pharmacovigilance study of the FDA adverse event reporting system (FAERS)
por: Ma, Pan, et al.
Publicado: (2022)

Proton pump inhibitors associated acute kidney injury and chronic kidney disease: data mining of US FDA adverse event reporting system
por: Wu, Bin, et al.
Publicado: (2021)

1783. Appropriateness of antibiotics use for patients with asymptomatic bacteriuria or urinary tract infection: A retrospective observational multicenter study in Korea
por: Jung, Jongtak, et al.
Publicado: (2022)

Fournier Gangrene Associated with Sodium-Glucose Cotransporter-2 Inhibitors: A Pharmacovigilance Study with Data from the U.S. FDA Adverse Event Reporting System
por: Hu, Yang, et al.
Publicado: (2020)

Severe cutaneous adverse reactions to drugs: A real-world pharmacovigilance study using the FDA Adverse Event Reporting System database
por: Li, Dongxuan, et al.
Publicado: (2023)

A pharmacovigilance study of association between proton pump inhibitor and dementia event based on FDA adverse event reporting system data
por: Wu, Bin, et al.
Publicado: (2021)

Drug-induced fall risk in older patients: A pharmacovigilance study of FDA adverse event reporting system database
por: Zhou, Shuang, et al.
Publicado: (2022)

Pharmacovigilance Study on Eosinophilic Pneumonia Induced by Anti-MRSA Agents: Analysis Based on the FDA Adverse Event Reporting System
por: Okada, Naoto, et al.
Publicado: (2023)

429. Risk of COVID-19 Related Deaths for SARS-CoV-2 Omicron (B.1.1.529) Compared With Delta (B.1.617.2): A Retrospective Cohort Study
por: Paulson, Shon, et al.
Publicado: (2023)

542. Evaluation of Remdesivir to the Outcomes of Hospitalized Patients with COVID-19 Infection in a Tertiary Care Hospital in Southern India
por: Raju, Jomel, et al.
Publicado: (2023)

Pharmacovigilance study of anti-infective-related acute kidney injury using the Japanese adverse drug event report database
por: Nakao, Satoshi, et al.
Publicado: (2021)

Risk factors of immune checkpoint inhibitor-associated acute kidney injury: evidence from clinical studies and FDA pharmacovigilance database
por: Chen, Pengwei, et al.
Publicado: (2023)

Serious Cardiovascular Adverse Events Associated with Hydroxychloroquine/Chloroquine Alone or with Azithromycin in Patients with COVID-19: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS)
por: Zhao, Ying, et al.
Publicado: (2022)

1407. Disproportionality Analysis of Safety with Nafcillin and Oxacillin with the FDA Adverse Event Reporting System (FAERS)
por: Timbrook, Tristan T, et al.
Publicado: (2018)

Pericardial Toxicities Associated With Immune Checkpoint Inhibitors: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS) Database
por: Ma, Zhuo, et al.
Publicado: (2021)

Pharmacovigilance study of the association between dipeptidyl peptidase–4 inhibitors and angioedema using the FDA Adverse Event Reporting System (FAERS)
por: Ohyama, Katsuhiro, et al.
Publicado: (2022)

Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System
por: Fusaroli, Michele, et al.
Publicado: (2022)

Post-marketing safety of immunomodulatory drugs in multiple myeloma: A pharmacovigilance investigation based on the FDA adverse event reporting system
por: Jiang, Tingting, et al.
Publicado: (2022)

Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database
por: Zhou, Chaozheng, et al.
Publicado: (2023)

A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say?
por: Cui, Zhiwei, et al.
Publicado: (2023)

Is There a Risk for Semaglutide Misuse? Focus on the Food and Drug Administration’s FDA Adverse Events Reporting System (FAERS) Pharmacovigilance Dataset
por: Chiappini, Stefania, et al.
Publicado: (2023)

Pharmacovigilance Analysis of Serious Adverse Events Reported for Biologic Response Modifiers Used as Prophylaxis against Transplant Rejection: a Real-World Postmarketing Experience from the US FDA Adverse Event Reporting System (FAERS)
por: Ali, A. K.
Publicado: (2013)

La Europa revolucionaria, 1783-1815 /
por: Rudé, George F. E.
Publicado: (1974)

The medical practitioners of provincial England in 1783.
por: Lane, J
Publicado: (1984)

John Syng Dorsey (1783-1818)
por: Middleton, William Shainline
Publicado: (1930)

Cannot write session to /tmp/vufind_sessions/sess_bmkdjpf0dr14r40ni505f2almo